Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several pregnancy/lactation and mechanism-of-action claims match the provided label excerpts, but multiple claims conflict with label details (e.g., contraception timing) and several claims are unsupported by the provided excerpts (e.g., DNA binding/bending details, clinical indication/child/informed trial absence, infant exposure evidence, breastfeeding molecular-weight rationale, availability of other drugs, pregnancy-warning comparison, lack of milk studies).
Category Scores
Accurate Statements
Lurbinectedin can cause fetal harm when administered to a pregnant woman (embryolethality at doses lower than the human dose).
Label excerpt 8.1 Pregnancy: "ZEPZELCA can cause fetal harm..." and "ZEPZELCA can cause embryolethality at doses lower than the human dose of 3.2 mg/m2".
Animal studies for lurbinectedin showed fetal harm (embryolethality/post-implantation loss in pregnant rats).
Label excerpt 8.1 Pregnancy, Data (Animal Data): "resulted in 100% post-implantation loss."
The package insert advises women not to breastfeed during treatment with ZEPZELCA and for 2 weeks after the last dose.
Label excerpt 8.2 Lactation: "advise women not to breastfeed during treatment... and for 2 weeks after the last dose."
Lurbinectedin binds guanine residues in the minor groove of DNA and forms adducts (mechanism includes minor groove binding).
Label excerpt 12.1 Mechanism of Action: "binds guanine residues in the minor groove of DNA, forming adducts".
Lurbinectedin can affect subsequent activity of DNA binding proteins including transcription factors (mechanistic language).
Label excerpt 12.1 Mechanism of Action: "Adduct formation triggers... can affect the subsequent activity of DNA binding proteins, including some transcription factors".
Unsupported Statements
Lurbinectedin does not have published reports of direct harm to infants once they are born.
Not supported by the provided label excerpts (8.1/8.2/8.3/8.4/12.1).
Lurbinectedin remains classified as pregnancy category D by the FDA.
Not supported by the provided label excerpts (they do not include pregnancy category statements).
No cases of live infants harmed by maternal exposure to lurbinectedin have been documented publicly.
Not supported by the provided label excerpts.
Animal reproduction studies of lurbinectedin consistently showed embryo-fetal toxicity in rats and rabbits.
Provided label excerpt only documents a study in pregnant rats (Gestation Day 10; 100% post-implantation loss). No rabbit data are included in the provided text.
The lurbinectedin package insert recommends effective contraception during treatment for women capable of childbearing.
Supported only in part by the excerpt (it states contraception during treatment, but the contraception duration claim is contradicted—see contradictions). The content itself is supported; this entry remains unsupported as phrased if it omits the required duration nuance. (See contradictions for the incorrect 6-month detail.)
No clinical trial or real-world registry has published outcomes for infants born to women who received lurbinectedin during pregnancy.
Not supported by the provided label excerpts.
The absence of published cases for lurbinectedin pregnancy exposure limits risk assessment beyond animal data.
Not stated in the provided excerpts (8.1 includes "There are no available data..." but does not assert how risk assessment is limited beyond animal data).
Regulators treat lurbinectedin as a potential risk rather than a proven danger to born infants.
Not supported by the provided label excerpts.
Lurbinectedin inhibits transcription.
Label excerpt states effects on transcription factors via adduct formation cascade, but does not explicitly state "inhibits transcription." Provided language is not an exact match.
Lurbinectedin is approved for previously treated metastatic small-cell lung cancer in adults.
The provided excerpts do not include Indications and Usage. No label support was provided for this claim.
Lurbinectedin is not indicated for use in children or infants.
Provided label excerpt 8.4 only states safety/effectiveness not established in pediatric patients, not an explicit "not indicated" statement.
Pediatric trials for lurbinectedin have not been completed.
Not supported by provided excerpt 8.4 (only "have not been established").
No studies have measured lurbinectedin in human breast milk.
Label excerpt 8.2 states there are no data on presence in human milk; that wording could be considered supported, but it is not exact. This is not quoted verbatim; however it is close to supported language. Marked unsupported due to exactness requirement.
Experts expect some excretion of lurbinectedin into breast milk.
Not supported by provided label excerpts.
Experts expect excretion into milk based on lurbinectedin's large molecular weight and lipophilic properties.
Not supported by provided label excerpts.
Manufacturers recommend avoiding breastfeeding during lurbinectedin treatment.
The label excerpt does recommend advising women not to breastfeed during treatment. As phrased, this is generally supported; however it is attributed to "manufacturers" rather than explicitly the label. Included here as unsupported due to attribution mismatch.
Topotecan and irinotecan remain available for the same indication as lurbinectedin.
Not supported by the provided excerpts.
Topotecan and irinotecan share similar pregnancy warnings.
Not supported by the provided excerpts.
Contradictions
Moderate
AI Statement
The lurbinectedin package insert recommends effective contraception for six months after treatment for women capable of childbearing.
Label Reference
Label excerpt 8.3 Females and Males of Reproductive Potential: "Advise female patients of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 7 months after the last dose."
Low
AI Statement
No clinical trial or real-world registry has published outcomes for infants born to women who received lurbinectedin during pregnancy.
Label Reference
Label excerpt 8.1 Pregnancy: "There are no available data to inform the risk of ZEPZELCA use in pregnant women."
Important Omissions
For female contraception, the label specifies 7 months after the last dose (and also includes male contraception durations), which the AI response did not fully and correctly present.
Importance:
Moderate
For pregnancy, the label also includes pregnancy testing prior to initiation for females of reproductive potential; the AI response did not mention this.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The most safety-relevant mismatch is the incorrect contraception duration after treatment (6 months stated vs 7 months per label). Other claims about pediatric use and lactation evidence sources are unsupported and could mislead if used clinically.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Incorrect contraception duration after last dose for females (AI: 6 months; label: 7 months).
Suggested Improvement
Update contraception timing to match label (7 months after last dose for females of reproductive potential; 4 months for males with female partners of reproductive potential). Avoid unsupported claims about absence of infant cases/registry outcomes and do not state mechanism outcomes (e.g., "inhibits transcription") unless verbatim/accurately reflected from label wording.